• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jason J. Luke, MD


  • Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, J√§nne PA.Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA.Clin Cancer Res. 2014 Mar 15;20(6):1698-705.
  • Luke JJ, Lezcano C, Hodi FS, Murphy GF.Antitumor Granuloma Formation by CD4+ T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Treatment With Ipilimumab.J Clin Oncol. 2014 Mar 10.
  • Luke JJ, Ott PA.Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?.Expert Opin Pharmacother. 2013 Dec;14(18):2457-62.
  • Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD.Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.Cancer. 2013 Oct 15;119(20):3687-95.
  • Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.J Clin Oncol. 2013 Sep 10;31(26):3182-90.
  • Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD.Ipilimumab for patients with advanced mucosal melanoma.Oncologist. 2013 Jun;18(6):726-32.
  • Luke JJ, Hodi FS.Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Oncologist. 2013 Jun;18(6):717-25.
  • Luke JJ, Schwartz GK.Chemotherapy in the management of advanced cutaneous malignant melanoma.Clin Dermatol.;31(3):290-7.
  • Luke JJ, Rubinstein LV, Smith GL, Ivy SP, Harris PJ.Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.Melanoma Res. 2013 Apr;23(2):152-8.
  • Luke J, Mirkin J, Bach P.Improving quality and addressing the rising costs of cancer care: two birds, one stone.J Oncol Pract. 2011 Nov;7(6):402-4.
  • Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK.The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and phase I clinical trial.Clin Cancer Res. 2012 Feb 28.
  • Luke JJ, Hodi FS.Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.Clin Cancer Res. 2012 Jan 1;18(1):9-14.
  • Bach PB, Mirkin JN, Luke JJ.Episode-based payment for cancer care: a proposed pilot for Medicare.Health Aff (Millwood). 2011 Mar;30(3):500-9.
  • Luke JJ, Van De Wetering CI, Knudson CM.Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability.Cell Death Differ. 2003 Jun;10(6):740-8.